Under the terms of the agreement, Qiagen receives an option to a worldwide non-exclusive commercial license to Epigenomics‘ proprietary mSEPT9 biomarker and DNA methylation technologies for the detection of colorectal cancer in blood.

The option can be exercised by Qiagen within the next two years and Epigenomics has granted Qiagen a research license to the mSEPT9 biomarker and the technologies.

Epigenomics will support Qiagen in the R&D phase through know-how transfer and the collection of clinical specimens as required.

Under the terms of the option agreement, Epigenomics will receive an upfront payment from Qiagen and will be reimbursed for any R&D support and clinical specimens provided during the R&D phase.

Upon Qiagen exercising the option Epigenomics would receive a further license payment.

With the agreement, Epigenomics continues to implement its dual business strategy of direct global commercialization of its colorectal cancer blood test, under its own brand name Epi proColon, and non-exclusive licensing of its proprietary mSEPT9 biomarker and DNA methylation technologies to leading companies in the diagnostic industry.